eHealthMe - Personalized health information & community eHealthMe - Personalized health information & community

Personalized health information & community

  Tools   Community
All drugs: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
All conditions: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Check symptoms       Compare drugs       Ask question       Write review       Answered/ Unanswered       Reviews

Would you have Interstitial lung disease when you have Hepatitis c?

Summary: Interstitial lung disease is found among people with Hepatitis c, especially people who are male, 50-59 old, also have Preventive health care, and take medication Rebetol.

We study 251 people who have Interstitial lung disease and Hepatitis c from FDA and social media. Find out below who they are, other conditions they have and drugs they take.

You are not alone: join a mobile support group for people who have Hepatitis c and Interstitial lung disease >>>





Hepatitis c

Hepatitis c can be treated by Ribavirin, Pegasys, Peginterferon, Incivek. (latest reports from 41,475 Hepatitis C patients)

Interstitial lung disease

Interstitial lung disease has been reported by people with rheumatoid arthritis, high blood pressure, lung cancer - non-small cell, osteoporosis, prostate cancer. (latest reports from 20,667 Interstitial lung disease patients)

On Mar, 4, 2015: 251 people who have hepatitis c and Interstitial Lung Disease are studied.

Trend of Interstitial lung disease in hepatitis c reports

Gender of people who have hepatitis c and experienced Interstitial lung disease * :

Interstitial lung disease34.15%65.85%

Age of people who have hepatitis c and experienced Interstitial lung disease * :

Interstitial lung disease0.48%0.00%0.00%0.00%1.91%10.74%31.03%55.85%

Severity of the symptom * :


Top co-existing conditions for these people * :

  1. Prophylaxis (27 people, 10.76%)
  2. Hypertension (23 people, 9.16%)
  3. Insomnia (12 people, 4.78%)
  4. Adverse event (11 people, 4.38%)
  5. Depression (11 people, 4.38%)
  6. Pain (10 people, 3.98%)
  7. Anxiety (8 people, 3.19%)
  8. Pulmonary fibrosis (6 people, 2.39%)
  9. Migraine with aura (6 people, 2.39%)
  10. Sedation (6 people, 2.39%)

Most common drugs used by these people * :

  1. Rebetol (215 people, 85.66%)
  2. Peg-intron (211 people, 84.06%)
  3. Pegasys (115 people, 45.82%)
  4. Ribavirin (115 people, 45.82%)
  5. Copegus (57 people, 22.71%)
  6. Urso 250 (50 people, 19.92%)
  7. Intron a (49 people, 19.52%)
  8. Aldactone (44 people, 17.53%)
  9. Lasix (44 people, 17.53%)
  10. Prilosec (26 people, 10.36%)

* Approximation only. Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Do you have Hepatitis C and Interstitial Lung Disease?

You are not alone! Join a mobile support group on :
- support group for people who have Interstitial Lung Disease and Hepatitis c
- support group for people who have Hepatitis c
- support group for people who have Interstitial Lung Disease

Could your drug cause:

Other conditions that could cause:

Recent related drug studies (Check your drugs):

Recent Hepatitis C related drug comparison:

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.


About - Terms of service - Privacy policy - Press - Testimonials - Contact us

© 2015 All rights reserved. Use of this site constitutes acceptance of's terms of service and privacy policy.